Patents Represented by Attorney Roman Saliwanchik

Find this attorney in the Justia Lawyer Directory

  • Mycobacterium fortuitum mutant
    Patent number: 4345034
    Abstract: Mutant which is used in a novel microbiological process to selectively transform steroids having 17-alkyl side chains of from 2 to 10 carbon atoms, inclusive, to yield androst-4-ene-3,17-dione (AD) as essentially the sole transformed product. AD is a valuable intermediate to make useful steroids.
    Type: Grant
    Filed: August 8, 1980
    Date of Patent: August 17, 1982
    Assignee: The Upjohn Company
    Inventors: Merle G. Wovcha, Kevin E. Brooks
  • Mycobacterium phlei mutants convert sterols to androsta-1,4-diene-3,17-dione and androsta-4-ene-3,17-dione
    Patent number: 4345029
    Abstract: Mutants which are used in a novel microbiological process to selectively degrade steroids having 17-alkyl side chains of from 2 to 10 carbon atoms, inclusive, to androsta-1,4-diene-3,17-dione (ADD) and androst-4-ene-3,17-dione (AD). ADD and AD are valuable intermediates to make useful steroids.
    Type: Grant
    Filed: September 8, 1980
    Date of Patent: August 17, 1982
    Assignee: The Upjohn Company
    Inventors: Merle G. Wovcha, Candice B. Biggs
  • Microorganism mutant conversion of sterols to androsta-4-ene-3,17-dione
    Patent number: 4345030
    Abstract: Mutant which is used in a novel microbiological process to selectively degrade steroids having 17-alkyl side chains of from 2 to 10 carbon atoms, inclusive, to yield predominantly androst-4-ene-3,17-dione (AD) and small amounts of androsta-1,4-diene-3,17-dione (ADD). AD is a valuable intermediate to make useful steroids.
    Type: Grant
    Filed: September 8, 1980
    Date of Patent: August 17, 1982
    Assignee: The Upjohn Company
    Inventors: Merle G. Wovcha, Candice B. Biggs
  • Mycobacterium fortuitum mutant
    Patent number: 4345033
    Abstract: Mutant which is used in a novel microbiological process to selectively degrade steroids having 17-alkyl side chains of from 2 to 10 carbon atoms, inclusive, to yield predominantly androst-4-ene-3,17-dione (AD) and small amounts of androsta-1,4-diene-3,17-dione (ADD). AD is a valuable intermediate to make useful steroids.
    Type: Grant
    Filed: September 8, 1980
    Date of Patent: August 17, 1982
    Assignee: The Upjohn Company
    Inventors: Merle G. Wovcha, Candice B. Biggs, Thomas R. Pyke
  • Hybrid plasmid of pBR322 and Streptomyces plasmid and E. coli containing same
    Patent number: 4343906
    Abstract: A process for cloning DNA into a suitable host, which comprises fragmenting said DNA to obtain fragmented DNA, ligating said fragmented DNA into a suitable vector to obtain chimeric (hybrid) DNA, and transforming said chimeric DNA into said ultimate host. By this process, the useful chemical plasmid pUC3, which is obtainable from a biologically pure culture of the microorganism Streptomyces sp. 3022a, NRRL 11441, is cloned into the well-known bacterium E. coli HB101. This cloning of pUC3 into E. coli HB101 enables the production of large amounts of plasmid pUC3 DNA. pUC3 is useful as a cloning vehicle in recombinant DNA work. For example, using recombinant DNA methodology, a desired gene, for example, the insulin gene, can be inserted into pUC3 and the resulting plasmid can then be transformed into a suitable host microbe which, upon culturing, produces the desired insulin.
    Type: Grant
    Filed: August 21, 1979
    Date of Patent: August 10, 1982
    Assignee: The Upjohn Company
    Inventors: Fritz Reusser, Vedpal S. Malik
  • Cointegrate plasmids and their construction from plasmids of Escherichia and Streptomyces
    Patent number: 4340674
    Abstract: Novel chemical compounds, cointegrate plasmids pUC1012 and pUC1013, which are obtained by covalent linkage of the E. coli plasmid pBR322 to the Streptomyces espinosus plasmid pUC6, and plasmids pUC1015 and pUC1022 which are obtained by restructuring plasmid pUC1012, and plasmids pUC1016 and pUC1023 which are obtained by restructuring plasmid pUC1013. These plasmids are useful as cloning vehicles in recombinant DNA work. For example, using DNA methodology, a desired gene, for example, the insulin gene, can be inserted into the plasmids and the resulting plasmids can then be transformed into a suitable host microbe which, upon culturing, produces the desired insulin.
    Type: Grant
    Filed: July 23, 1980
    Date of Patent: July 20, 1982
    Assignee: The Upjohn Company
    Inventors: Jack J. Manis, Sarah K. Highlander
  • Biologically pure culture of mutant mycobacterium
    Patent number: 4339539
    Abstract: Mutants which are used in a novel microbiological process to selectively degrade steroids having 17-alkyl side chains of from 2 to 10 carbon atoms, inclusive, to androsta-1,4-diene-3,17-dione (ADD) and androst-4-ene-3,17-dione (AD). ADD and AD are valuable intermediates to make useful steroids.
    Type: Grant
    Filed: September 8, 1980
    Date of Patent: July 13, 1982
    Assignee: The Upjohn Company
    Inventors: Merle G. Wovcha, Candice B. Biggs, Thomas R. Pyke
  • Co-integrate plasmids and their construction from plasmids of Escherichia and Streptomyces
    Patent number: 4338400
    Abstract: Novel chemical compounds, recombinant plasmids pUC1026 and pUC1027, which are obtained by covalent linkage of the E. coli plasmid pBR322 to the Streptomyces espinosus plasmid pUC6. These plasmids are produced by a novel process which can be used to stabilize unstable potential plasmid vectors. These plasmids are useful as cloning vehicles in recombinant DNA work. For example, using DNA methodology, a desired gene, for example, the insulin gene, can be inserted into the plasmids and the resulting plasmids can then be transformed into a suitable host microbe which, upon culturing, produces the desired insulin. The stabilization process disclosed herein can be used to make other stable plasmids.
    Type: Grant
    Filed: January 26, 1982
    Date of Patent: July 6, 1982
    Assignee: The Upjohn Company
    Inventors: Jack J. Manis, Sarah K. Highlander
  • Paulomycin A and B and preparation thereof
    Patent number: 4335108
    Abstract: Disclosed and claimed is an improved fermentation process for preparing the known antibiotic U-43,120, herein referred to as paulomycin. Also disclosed and claimed are the novel and useful antibiotics paulomycin A and paulomycin B.
    Type: Grant
    Filed: August 25, 1980
    Date of Patent: June 15, 1982
    Assignee: The Upjohn Company
    Inventors: Alexander D. Argoudelis, Vincent P. Marshall, Leroy E. Johnson
  • Construction of co-integrate plasmids from plasmids of Streptomyces and Escherichia
    Patent number: 4332900
    Abstract: Novel chemical compounds, recombinant plasmids pUC1019 and pUC-1020, which are obtained by covalent linkage of ca. 4.2 kb BclI restriction endonuclease fragment of the Streptomyces espinosus plasmid pUC6 into the BamHI endonuclease site of the E. coli plasmid pBR322. Plasmid pUC1024 is obtained by restructuring plasmid pUC1019. These plasmids are useful as cloning vehicles in recombinant DNA work. For example, using DNA methodology, a desired gene, for example, the insulin gene, can be inserted into the plasmids and the resulting plasmids can then be transformed into a suitable host microbe which, upon culturing, produces the desired insulin.
    Type: Grant
    Filed: October 1, 1980
    Date of Patent: June 1, 1982
    Assignee: The Upjohn Company
    Inventors: Jack J. Manis, Sarah K. Highlander
  • Hybrid plasmid and process of making same
    Patent number: 4332898
    Abstract: A novel chemical compound, plasmid pUC1021, which was constructed from Bacillus megaterium chromosomal DNA and plasmid pBR322. Hybrid plasmid pUC1021 contains a functional tet gene promoter, and, thus, is useful as a cloning vehicle in recombinant DNA work. For example, using well known DNA methodology, a desired gene, for example, the insulin gene, can be inserted into pUC1021 and the resulting plasmid can then be transformed into a suitable host microbe which, upon culturing, produces the desired insulin.
    Type: Grant
    Filed: June 16, 1980
    Date of Patent: June 1, 1982
    Assignee: The Upjohn Company
    Inventor: Fritz Reusser
  • Antibiotic U-62,162 and process of making
    Patent number: 4331659
    Abstract: Novel antibiotic U-62,162 producible in a fermentation under controlled conditions using a man-made biologically pure culture of the microorganism Streptomyces verdensis, Dietz and Li sp.n., NRRL 12256. This antibiotic is strongly active against various Gram-positive bacteria, for example, Staphylococcus aureus. Thus, antibiotic U-62,162 can be used in various environments to eradicate or control such bacteria.
    Type: Grant
    Filed: September 10, 1980
    Date of Patent: May 25, 1982
    Assignee: The Upjohn Company
    Inventors: Herman Hoeksema, Libor Slechta
  • Mycobacterium fortuitum strain
    Patent number: 4329432
    Abstract: Novel compounds prepared by microbial transformation using novel mutants to selectively degrade steroids with or without 17-alkyl side chains of from 2 to 10 carbon atoms, inclusive. These compounds can be used as intermediates to make useful steroids.
    Type: Grant
    Filed: August 28, 1980
    Date of Patent: May 11, 1982
    Assignee: The Upjohn Company
    Inventors: John C. Knight, Merle G. Wovcha
  • Nogalamycin analog containing compounds
    Patent number: 4329450
    Abstract: Novel regioselective acylates of the antibiotic nogalamycin and its dimethylamino-retaining analogs are prepared by a selective acylation procedure. The compounds of the invention have antibacterial activity, and, thus, can be used in various environments to control or eradicate susceptible bacteria.
    Type: Grant
    Filed: February 25, 1981
    Date of Patent: May 11, 1982
    Assignee: The Upjohn Company
    Inventor: Paul F. Wiley
  • Mycobacterium fortuitum strain
    Patent number: 4328315
    Abstract: Mutants which are used in a novel microbiological process to selectively degrade steroids having 17-alkyl side chains of from 2 to 10 carbon atoms, inclusive, to androsta-1,4-diene-3,17-dione (ADD) and androst-4-ene-3,17-dione (AD). ADD and AD are valuable intermediates to make useful steroids.
    Type: Grant
    Filed: September 8, 1980
    Date of Patent: May 4, 1982
    Assignee: The Upjohn Company
    Inventors: Merle G. Wovcha, Candice B. Biggs, Thomas R. Pyke
  • Saccharopolyspora culture
    Patent number: 4321329
    Abstract: A process for preparing the antibiotic U-59,760. The process is a microbiological process using a biologically pure culture of the novel microbe Saccharopolyspora hirsuta strain 367, NRRL 12045. The antibiotic produced by the process is active against various microorganisms, for example, Staphylococcus aureus, Streptococcus pyogenes, and Klebsiella pneumoniae. Thus, antibiotic U-59,760 can be used in various environments to eradicate or control such bacteria.
    Type: Grant
    Filed: October 6, 1980
    Date of Patent: March 23, 1982
    Assignee: The Upjohn Company
    Inventors: Howard A. Whaley, John H. Coats
  • Process for the purification of lincomycin
    Patent number: 4317903
    Abstract: A recovery process, using a reverse-phase high performance preparative liquid chromatography (hpplc) which gives a highly pure preparation of the useful antibiotic lincomycin hydrochloride. While giving a highly pure preparation of lincomycin hydrochloride, wherein less than about 0.5% of lincomycin B hydrochloride is present, the process also yields analytically pure lincomycin B hydrochloride which can be used as a laboratory standard.
    Type: Grant
    Filed: January 26, 1981
    Date of Patent: March 2, 1982
    Assignee: The Upjohn Company
    Inventor: John R. Hofstetter
  • Process of producing 3-trehalosamine by fermentation
    Patent number: 4310627
    Abstract: Novel antibiotic 3-trehalosamine (U-59,834) producible in a fermentation under controlled conditions using the new microorganism Nocardiopsis trehalosei sp. nov., NRRL 12026.This antibiotic is active against Gram-positive bacteria, for example, Staphylococcus aureus, Bacillus subtilis, and Diplococcus pneumoniae. Thus, 3-trehalosamine can be used in various environments to eradicate or control such bacteria.
    Type: Grant
    Filed: October 9, 1980
    Date of Patent: January 12, 1982
    Assignee: The Upjohn Company
    Inventors: Lester A. Dolak, Alice L. Laborde, Thomas M. Castle
  • Lincomycin compounds
    Patent number: 4310660
    Abstract: Novel useful analogs of the well known antibiotics lincomycin and clindamycin. These analogs are prepared by condensing a cyclic acid with a sugar amine.
    Type: Grant
    Filed: October 6, 1980
    Date of Patent: January 12, 1982
    Assignee: The Upjohn Company
    Inventor: Robert D. Birkenmeyer
  • Lincomycin compounds
    Patent number: 4309533
    Abstract: Novel useful analogs of the well known antibiotics lincomycin and clindamycin. These analogs are prepared by condensing a cyclic acid with a sugar amine.
    Type: Grant
    Filed: October 6, 1980
    Date of Patent: January 5, 1982
    Assignee: The Upjohn Company
    Inventor: Robert D. Birkenmeyer